Metabolic heterogeneity in cancer
- PMID: 38267631
- DOI: 10.1038/s42255-023-00963-z
Metabolic heterogeneity in cancer
Abstract
Cancer cells rewire their metabolism to survive during cancer progression. In this context, tumour metabolic heterogeneity arises and develops in response to diverse environmental factors. This metabolic heterogeneity contributes to cancer aggressiveness and impacts therapeutic opportunities. In recent years, technical advances allowed direct characterisation of metabolic heterogeneity in tumours. In addition to the metabolic heterogeneity observed in primary tumours, metabolic heterogeneity temporally evolves along with tumour progression. In this Review, we summarize the mechanisms of environment-induced metabolic heterogeneity. In addition, we discuss how cancer metabolism and the key metabolites and enzymes temporally and functionally evolve during the metastatic cascade and treatment.
© 2024. Springer Nature Limited.
Similar articles
-
Metabolic Potential of Cancer Cells in Context of the Metastatic Cascade.Cells. 2020 Sep 5;9(9):2035. doi: 10.3390/cells9092035. Cells. 2020. PMID: 32899554 Free PMC article. Review.
-
Metabolic heterogeneity in cancer: An overview and therapeutic implications.Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188421. doi: 10.1016/j.bbcan.2020.188421. Epub 2020 Aug 22. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32835766 Review.
-
Defining a metabolic landscape of tumours: genome meets metabolism.Br J Cancer. 2020 Jan;122(2):136-149. doi: 10.1038/s41416-019-0663-7. Epub 2019 Dec 10. Br J Cancer. 2020. PMID: 31819196 Free PMC article. Review.
-
Metabolic Flexibility Is a Determinant of Breast Cancer Heterogeneity and Progression.Cancers (Basel). 2021 Sep 19;13(18):4699. doi: 10.3390/cancers13184699. Cancers (Basel). 2021. PMID: 34572926 Free PMC article. Review.
-
Cancer metabolism: looking forward.Nat Rev Cancer. 2021 Oct;21(10):669-680. doi: 10.1038/s41568-021-00378-6. Epub 2021 Jul 16. Nat Rev Cancer. 2021. PMID: 34272515 Review.
Cited by
-
Hybrid-integrated devices for mimicking malignant brain tumors ("tumor-on-a-chip") for in vitro development of targeted drug delivery and personalized therapy approaches.Front Med (Lausanne). 2024 Nov 19;11:1452298. doi: 10.3389/fmed.2024.1452298. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39629230 Free PMC article. Review.
-
Advances in molecular pathology and therapy of non-small cell lung cancer.Signal Transduct Target Ther. 2025 Jun 15;10(1):186. doi: 10.1038/s41392-025-02243-6. Signal Transduct Target Ther. 2025. PMID: 40517166 Free PMC article. Review.
-
Spatiotemporal metabolomic approaches to the cancer-immunity panorama: a methodological perspective.Mol Cancer. 2024 Sep 18;23(1):202. doi: 10.1186/s12943-024-02113-9. Mol Cancer. 2024. PMID: 39294747 Free PMC article. Review.
-
2D versus 3D tumor-on-chip models to study the impact of tumor organization on metabolic patterns in vitro.Sci Rep. 2025 Jun 4;15(1):19506. doi: 10.1038/s41598-025-03504-8. Sci Rep. 2025. PMID: 40461567 Free PMC article.
-
Fatty Acid Metabolism Provides an Essential Survival Signal in OxPhos and BCR DLBCL Cells.Biomedicines. 2025 Mar 13;13(3):707. doi: 10.3390/biomedicines13030707. Biomedicines. 2025. PMID: 40149683 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical